Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120110 | 0.84 | KMT2A (0.51) | KMT2ALMNAMT-CO2ATRHSP90AA1 | |
| SCHEMBL3484770 | 0.83 | KMT2A (0.50) | KMT2ALMNAMT-CO2ATRSYK | |
| SCHEMBL26663206 | 0.81 | KMT2A (0.48) | KMT2ALMNAMT-CO2ATRSYK | |
| SCHEMBL30548350 | 0.79 | LMNA (0.47) | KMT2ALMNAMT-CO2ATRSYK | |
| SCHEMBL26188589 | 0.79 | LMNA (0.47) | KMT2ALMNAMT-CO2ATRSYK | |
| SCHEMBL3804334 | 0.75 | GRM5 (0.33) | KMT2ALMNAATRHSP90AA1HSP90AB1 | |
| SCHEMBL8126885 | 0.74 | POLB (0.47) | KMT2ALMNARAB9AMEN1SMN1; SMN2 | |
| SCHEMBL8723112 | 0.73 | KDM4E (0.34) | SYKRAB9A | |
| SCHEMBL551649 | 0.71 | MT-CO2 (0.53) | KMT2ALMNAMT-CO2MEN1SMN1; SMN2 | |
| SCHEMBL2529611 | 0.71 | MT-CO2 (0.42) | MT-CO2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | KMT2A 1412/4885LMNA 1456/4885MT-CO2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.